2243284-19-5
Chemical Structure
Bimokalner
Synonym(s): Bimokalnerum
- CAS No.: 2243284-19-5
- Formula:C15H18F5NOS
- Molecular Weight:355.37
InChIKey: KTTBVFVRXDRSSP-OSMZGAPFSA-N
SMILES: FS(F)(F)(F)(F)C1=CC=CC(CNC([C@@H]2[C@]3([H])C[C@](CC3)([H])C2)=O)=C1
Biological Activity: Bimokalner (Bimokalnerum) is a Kv7.4 voltage-gated potassium channel agonist. Bimokalner activates potassium channels to modulate specific molecular targets in outer hair cells, thereby preventing Cisplatin (HY-17394)-induced damage. Bimokalner can be used in research on Cisplatin-induced sensorineural hearing loss and ototoxicity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bimokalner | Bimokalner (Bimokalnerum) is a Kv7.4 voltage-gated potassium channel agonist. Bimokalner activates potassium channels to modulate specific molecular targets in outer hair cells, thereby preventing Cisplatin (HY-17394)-induced damage. Bimokalner can be used in research on Cisplatin-induced sensorineural hearing loss and ototoxicity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Internacionales DC. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2023;37(2).
- [2]. Clarke H. ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer. Urology Times. 2026 Jul 1;54(5):7.
- [3]. Prävention eines Hörverlusts bei Cisplatin-Therapie des Hodentumors. Aktuelle Urol. 2025 Dec;56(6):526-527. German.